Biotechnology is a more and more important field of research in present. Publicly we are currently confronted with many questions about the rights and wrongs within this field of science, like how to handle the issue of gene manipulation or stem cell research. However, biotechnology is more than just an accumulation of ethical questions and science – it is a whole industry and as such interesting for investors.
The scope of this paper is not dealing with the topics discussed in glossy magazines, but it addresses the issues of corporate finance in biotechnology. In order to get an overview of the industry from a finance point of view, the industry has to be portrayed. Hence, this is the topic of chapter two.
From the point of the investors, and therefore of the capital markets, the understandability of the segment biotechnology, and thus the availability of crucial information has to be ensured.
Consequently the transparency of the biotechnology segment and of the individual enterprises, respectively, are the topics of the third chapter. The implications of this chapter have a strong impact on the valuation of biotechnological companies and the sector as a whole – a subject dealt with in chapter number four.
The fifth chapter is concerned with the core topic of this paper and identifies and analyses different sources of finance for biotechnology enterprises. Thereby it is taking the point of view of the biotechnology firms and the potential investors. The paper is showing important difficulties and advantages connected with the different approaches. Additionally the chapter also describes and evaluates the risks of different options of investors.
The paper is concluded with a summary of the findings in chapter six showing that investing into biotechnology is worth thinking about for a responsible and sophisticated investor, although the segment is a difficult field incurring many risks, however opportunities for the “big win”, as well.
Table of Contents
1. Introduction
2. Life Science – An Overview
2.1 Red, Green and White Life Science – What is the difference?
2.2 Current Trends in the Biotech Segment
2.3 Business Models in Biotech
3. Transparency in the Biotechnology Sector
3.1 Specifics in Investor Relations
3.2 Specifics in Corporate Governance
3.3 Specifics in Financial Accounting and Reporting
4. Company and Sector Valuation
4.1 Valuation Approaches
4.2 Five-Forces Model for the Sector
4.3 Traditional Valuation and Specifics for Biotech
4.4 Specifics for Pharmaceutical Development
4.5 Specifics for Technology- / Service- Providers
5. Financing Sources
5.1 Initial Financial Sourcing
5.1.1 Governmental Funds and Politics
5.1.2 Incubation Concept
5.1.3 Private Equity
5.1.4 Venture Capital
5.1.5 Business Angles
5.1.6 Strategic Investments and Other Financing Possibilities
5.2 Secondary Financial Sourcing
5.3 Investor's Strategies
5.3.1 Direct investments
5.3.2 Private Equity Funds
5.3.3 Fund-of-Funds
5.3.4 Comparison of Risk Profiles
5.3.5 Alternative Investment Vehicles
5.4 Exit Options for Initial Capital Providers
6. Summary
Objectives & Core Topics
This paper examines the specific corporate finance challenges within the biotechnology industry, focusing on the identification, analysis, and evaluation of diverse financial sources available to biotech enterprises from both the firm's and the investor's perspective.
- Analysis of biotechnology industry characteristics and business models
- Transparency requirements and investor relations in the biotech sector
- Evaluation of valuation methodologies for high-risk innovation-driven companies
- Assessment of initial and secondary financial sourcing strategies
- Evaluation of investor strategies and associated risk profiles
Excerpt from the Book
5.1.4 Venture Capital
Venture Capital (VC), often also referred to as risk capital, has been the most important source of finance for German biotechnology companies in during the last decade – up to 2003 it has actually been the only source, except for governmental programs. The total amount of venture capital in the biotechnology segment realized a growth rate of an average of 5 % (not including the boom years 2000 and 2001).
Usually biotechnology start ups are not able to acquire enough finance to do the necessary investments into their research and development capacities out of their revenues. Venture Capitalists offer the necessary financial muscles to get the researchers ideas into a marketable product. Therefore they usually acquire a large amount of the start up providing equity to the enterprise and getting a share in the company in return. However, to convince a Venture Capitalist to join a biotechnology enterprise, the founders have to fulfill certain criteria. A necessary prerequisite is a profound business plan. Venture Capitalists may demand seats in the board of directors of the start up enterprise demanding not only a certain control, but also offering expertise concerning judgment of contracts. The investment of the founders' (and managers' and researchers') private fortunes into the start up signals to Venture Capitalists their faith in the business. It also creates a very strong commitment of the involved persons to their project which in turn is taken positively into consideration by Venture Capitalists. Furthermore Venture Capitalists usually collaterise their investment by choosing a model consisting of preferable shares that convert into ordinary shares in case of profitability and into super senior liabilities in case of a failure.
Chapter Summary
1. Introduction: The introduction outlines the scope of the paper, focusing on corporate finance within the biotechnology industry and the necessity of understanding its specific risks and potential.
2. Life Science – An Overview: This chapter defines life sciences and biotechnology, distinguishes between red, green, and white biotechnology, and identifies current industry trends and business models.
3. Transparency in the Biotechnology Sector: It addresses the critical role of investor relations, corporate governance, and financial reporting standards in maintaining investor trust in non-profitable biotech firms.
4. Company and Sector Valuation: This chapter analyzes the difficulties of applying traditional valuation methods to biotech firms and suggests hybrid approaches that account for specific value drivers like product pipelines.
5. Financing Sources: The chapter explores the landscape of financial sourcing, from governmental support and incubation concepts to private equity, venture capital, and secondary market financing, while evaluating investor strategies and risks.
6. Summary: The summary synthesizes the paper's findings, concluding that while biotech is a high-risk sector, it offers significant potential for sophisticated investors who utilize appropriate diversification strategies.
Keywords
Biotechnology, Corporate Finance, Venture Capital, Private Equity, Valuation, Investor Relations, Corporate Governance, Life Sciences, R&D, Start-ups, Financial Sourcing, Risk Management, IPO, Trade Sale, Incubation Concept
Frequently Asked Questions
What is the primary focus of this publication?
The work focuses on corporate finance issues within the biotechnology sector, specifically identifying and evaluating various funding sources for biotech companies.
Which key sectors are covered in terms of color differentiation?
The paper distinguishes between red (health/medical), green (agricultural), and white (industrial) biotechnology, with a primary focus on red biotechnology due to its high market interest.
What is the central research question regarding company valuation?
It explores how to appropriately value biotechnology companies, given that traditional methods are often insufficient due to long R&D periods and high innovation risks.
Which scientific and financial methods are considered for valuation?
The author discusses a mixture of approaches, including DCF, peer-group benchmarking, and specialized Biotechnology Discount Models, complemented by qualitative analysis.
What is covered in the financing section?
The section treats initial financial sourcing (government, incubation, VC, private equity) and secondary sourcing, alongside a detailed analysis of investor strategy vehicles.
Which terminology characterizes the investment strategies discussed?
Key terms include direct investments, private equity funds, fund-of-funds, and alternative investment vehicles like Collateralized Fund Obligations.
How do governmental funds specifically support German biotech start-ups?
The government provides programs like GO-Bio, research subsidies, and support for investment trusts to hedge default risks and foster innovation.
What is the significance of the "incubation concept"?
Incubators help young biotech firms overcome resource allocation inefficiencies by providing infrastructure, advisory services, and networking, significantly impacting mid-term development.
How does the author characterize the risk profile of VC investments?
The paper illustrates that direct VC investments carry high risks of total loss, suggesting that diversification through funds or fund-of-funds is preferred for most investors.
- Quote paper
- Christian Strassburger (Author), 2006, Financing in life sciences biotech companies, Munich, GRIN Verlag, https://www.grin.com/document/70419
